|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1982-8-14
|
|
pubmed:abstractText |
[(14)C]Stearic acid-labeled cerebroside sulfate (CS) was presented to cultured skin fibroblasts in the media. After endocytosis into control cells 86% was readily metabolized to galactosylceramide, ceramide, and stearic acid, which was reutilized in the synthesis of the major lipids found in cultured fibroblasts. Uptake and metabolism of the [(14)C]CS into cells from typical and atypical patients and carriers of metachromatic leukodystrophy (MLD), Krabbe disease, and Farber disease were observed. Cells from patients with late infantile MLD could not metabolize the CS at all, while cells from an adult MLD patient and from a variant MLD patient could metabolize approximately 40 and 15%, respectively, of the CS taken up. These results are in contrast to the in vitro results that demonstrated a severe deficiency of arylsulfatase A in the late infantile and adult patient and a partial deficiency (21-27% of controls) in the variant MLD patient. Patients with Krabbe disease could metabolize nearly 40% of the galactosylceramide produced in the lysosomes from the CS. This is in contrast to the near zero activity for galactosylceramidase measured in vitro. Carriers of Krabbe disease with galactosylceramidase activity near half normal in vitro and those with under 10% of normal activity were found to metabolize galactosylceramide in cells significantly slower than controls. This provides a method for differentiating affected patients from carriers with low enzyme activity in vitro. Cells from patients with Farber disease could catabolize only approximately 15% of the ceramide produced from galactosylceramide. This technique provides a method for the identification of typical and atypical patients and carriers of three genetic diseases using one substrate.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-1138177,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-1145196,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-1245944,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-13315506,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-14907713,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-15452,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-25315,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-41211,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-4194292,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-4284220,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-4296328,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-4302302,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-4698260,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-5123204,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-5794918,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-6104322,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-6107060,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-6117597,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-6119902,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-699360,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-7259198,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-7287002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-731265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-7354254,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-8599,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6806321-932904
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0021-9738
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
89-97
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:6806321-Amidohydrolases,
pubmed-meshheading:6806321-Cells, Cultured,
pubmed-meshheading:6806321-Ceramidases,
pubmed-meshheading:6806321-Cerebrosides,
pubmed-meshheading:6806321-Fatty Acids,
pubmed-meshheading:6806321-Fibroblasts,
pubmed-meshheading:6806321-Galactosylceramides,
pubmed-meshheading:6806321-Heterozygote Detection,
pubmed-meshheading:6806321-Humans,
pubmed-meshheading:6806321-Lactose Intolerance,
pubmed-meshheading:6806321-Lactosylceramides,
pubmed-meshheading:6806321-Leukodystrophy, Globoid Cell,
pubmed-meshheading:6806321-Leukodystrophy, Metachromatic,
pubmed-meshheading:6806321-Lysosomes,
pubmed-meshheading:6806321-Sphingolipidoses
|
|
pubmed:year |
1982
|
|
pubmed:articleTitle |
Diagnosis of metachromatic leukodystrophy, Krabbe disease, and Farber disease after uptake of fatty acid-labeled cerebroside sulfate into cultured skin fibroblasts.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
